Abstract
In the last decades, the treatment of obsessive-compulsive disorder (OCD) has been revolutioned by the introduction into the clinical practice of the selective serotonin (5-HT) reuptake inhibitors (SSRIs), following the observation of the unique response of OCD patients to clomipramine. However, if with no doubt the 5-HT system is central to the pharmacological treatment of OCD, it is unlikely that it represents the whole story. In fact, different studies suggest abnormalities of other neurotransmitters, neuropeptides or second messengers, so that it can be hypothesized that the possible heterogeneity of pathophysiological mechanisms might underlie the different clinical pictures and responses to treatment. Moreover, latest developments in the pharmacology of SSRIs have shown that they share the common property of 5-HT reuptake blockade, but, with the exception of citalopram and escitalopram, they do interact with other receptors and systems. In this paper, the latest findings on pharmacological treatments of OCD will be reviewed, together with a focus on putative targets for future drugs, such as the glutamate system or second messengers, and the problems related to treating OCD in different ages.
Keywords: Obsessive-compulsive disorder, pharmacological treatment, antidepressants, clomipramine, selective serotonin reuptake inhibitors, resistance, anti-obsessive new compounds, Obsessions, Compulsions, anxiety, symptoms, tricyclic antidepressant, pathophysiology, ECA survey, psychotherapy, (ERP), Y-BOCS, chronic, agitation, insomnia, nausea, gastro-intestinal distress, (rTMS), dorsolateral prefrontal cortex, deep brain stimulation, neurosurgery, bilateral ante-rior capsulotomy, cingulotomy, leucotomy, subcaudate tractotomy, inositol, D-cycloserine, riluzole, morphine, cyto-chrome P450, Fluvoxamine, Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, (SNRIs), Venlafaxine, Duloxetine, Pindolol, (SPECT), N-methyl-D-aspartate, Memantine, egodystonia, PANDAS, augmentation
Current Medicinal Chemistry
Title: Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder
Volume: 17 Issue: 29
Author(s): D. Marazziti, G. Consoli, S. Baroni and M. Catena Dell'Osso
Affiliation:
Keywords: Obsessive-compulsive disorder, pharmacological treatment, antidepressants, clomipramine, selective serotonin reuptake inhibitors, resistance, anti-obsessive new compounds, Obsessions, Compulsions, anxiety, symptoms, tricyclic antidepressant, pathophysiology, ECA survey, psychotherapy, (ERP), Y-BOCS, chronic, agitation, insomnia, nausea, gastro-intestinal distress, (rTMS), dorsolateral prefrontal cortex, deep brain stimulation, neurosurgery, bilateral ante-rior capsulotomy, cingulotomy, leucotomy, subcaudate tractotomy, inositol, D-cycloserine, riluzole, morphine, cyto-chrome P450, Fluvoxamine, Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, (SNRIs), Venlafaxine, Duloxetine, Pindolol, (SPECT), N-methyl-D-aspartate, Memantine, egodystonia, PANDAS, augmentation
Abstract: In the last decades, the treatment of obsessive-compulsive disorder (OCD) has been revolutioned by the introduction into the clinical practice of the selective serotonin (5-HT) reuptake inhibitors (SSRIs), following the observation of the unique response of OCD patients to clomipramine. However, if with no doubt the 5-HT system is central to the pharmacological treatment of OCD, it is unlikely that it represents the whole story. In fact, different studies suggest abnormalities of other neurotransmitters, neuropeptides or second messengers, so that it can be hypothesized that the possible heterogeneity of pathophysiological mechanisms might underlie the different clinical pictures and responses to treatment. Moreover, latest developments in the pharmacology of SSRIs have shown that they share the common property of 5-HT reuptake blockade, but, with the exception of citalopram and escitalopram, they do interact with other receptors and systems. In this paper, the latest findings on pharmacological treatments of OCD will be reviewed, together with a focus on putative targets for future drugs, such as the glutamate system or second messengers, and the problems related to treating OCD in different ages.
Export Options
About this article
Cite this article as:
Marazziti D., Consoli G., Baroni S. and Catena Dell'Osso M., Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176384
DOI https://dx.doi.org/10.2174/092986710793176384 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Small Molecule Modulation of p75 Neurotrophin Receptor Functions
CNS & Neurological Disorders - Drug Targets Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Interaction of Dehydrogenase Enzymes with Nanoparticles in Industrial and Medical Applications, and the Associated Challenges: A Mini-review
Mini-Reviews in Medicinal Chemistry Partnerships Between Philanthropy, Government and Investors are Needed to Advance Drug Discovery for Neurodegenerative Diseases
Current Alzheimer Research Synthetic Methods for the Preparation of Triazepandiones and Review of their Applications
Current Organic Chemistry Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification
Current Stem Cell Research & Therapy JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Commentary ( Two Hits with One Shot – A Possibility of Simultaneous Targeting Motor Neuron Loss and Depression in ALS by Upregulating ADAR2 )
CNS & Neurological Disorders - Drug Targets RNA Interference and Amyotrophic Lateral Sclerosis
Current Drug Metabolism Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Commentary [ Research Highlights(To miR or Not to miR: That is the Question in ALS Disease ]
CNS & Neurological Disorders - Drug Targets Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Current Pharmaceutical Design